Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PBYI 
Puma Biotechnology Inc (PBYI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/10/2025: PBYI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.92% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 257.90M USD | Price to earnings Ratio 5.17 | 1Y Target Price 3 |
Price to earnings Ratio 5.17 | 1Y Target Price 3 | ||
Volume (30-day avg) 2 | Beta 1.38 | 52 Weeks Range 2.32 - 6.07 | Updated Date 10/12/2025 |
52 Weeks Range 2.32 - 6.07 | Updated Date 10/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.99 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.35% | Operating Margin (TTM) 12.66% |
Management Effectiveness
Return on Assets (TTM) 14.4% | Return on Equity (TTM) 63.24% |
Valuation
Trailing PE 5.17 | Forward PE 3.46 | Enterprise Value 216141174 | Price to Sales(TTM) 1.08 |
Enterprise Value 216141174 | Price to Sales(TTM) 1.08 | ||
Enterprise Value to Revenue 0.91 | Enterprise Value to EBITDA 3.42 | Shares Outstanding 50370723 | Shares Floating 38562818 |
Shares Outstanding 50370723 | Shares Floating 38562818 | ||
Percent Insiders 15.43 | Percent Institutions 68.38 |
Upturn AI SWOT
Puma Biotechnology Inc
Company Overview
History and Background
Puma Biotechnology, Inc. was founded in 2011. It focuses on the development and commercialization of innovative products to enhance cancer care. It has primarily focused on the commercialization of its drug, NERLYNX (neratinib).
Core Business Areas
- Oncology Therapeutics: Development and commercialization of therapies for cancer treatment. Primarily focuses on NERLYNX for HER2-positive breast cancer.
Leadership and Structure
Alan H. Auerbach serves as the Chief Executive Officer, President and Chairman. The company has a standard organizational structure for a publicly traded biotechnology company, including departments focused on research and development, commercial operations, finance, and administration.
Top Products and Market Share
Key Offerings
- NERLYNX (neratinib): An oral tyrosine kinase inhibitor approved for extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. Market share data is hard to explicitly determine due to treatment combinations. Key competitors are other HER2-targeted therapies, as well as other adjuvant therapies for breast cancer, some being generics. Actual revenue in 2023 was $120.9 million.
Market Dynamics
Industry Overview
The oncology therapeutics market is highly competitive and rapidly evolving, driven by advancements in cancer biology, drug development technologies, and regulatory pathways. The market is characterized by high unmet needs, increasing prevalence of cancer, and growing demand for personalized medicine.
Positioning
Puma Biotechnology is positioned as a player focusing on HER2-positive breast cancer. Its competitive advantage comes from NERLYNX, which is used after adjuvant trastuzumab-based therapy to reduce the risk of recurrence.
Total Addressable Market (TAM)
The global breast cancer therapeutics market is estimated at over $25 billion. Puma's TAM is focused on the HER2-positive segment, representing a significant portion of the overall market. Positioning relative to TAM is strong for appropriate patient profiles that meet their treatment guidelines.
Upturn SWOT Analysis
Strengths
- Approved and commercialized product (NERLYNX)
- Established sales and marketing infrastructure
- Experienced management team
- Focus on a specific cancer subtype
Weaknesses
- Reliance on a single product (NERLYNX)
- Competition from established and emerging therapies
- Market acceptance challenges due to side effects
- Relatively small size compared to larger pharmaceutical companies
Opportunities
- Potential for expansion into new markets
- Development of new formulations or indications for NERLYNX
- Acquisition or licensing of new assets
- Partnerships with other pharmaceutical companies
Threats
- Generic competition
- Clinical trial failures
- Regulatory changes
- Adverse events or safety concerns
Competitors and Market Share
Key Competitors
- ROSY
- NVS
- PFE
Competitive Landscape
Puma Biotechnology faces intense competition from larger pharmaceutical companies with established oncology franchises. Puma's advantage lies in its focus on a specific cancer subtype and NERLYNX's unique mechanism of action.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven primarily by NERLYNX sales, though growth has slowed due to competition.
Future Projections: Future growth depends on the company's ability to expand NERLYNX's market share, develop new products, and achieve profitability. Analyst estimates suggest moderate growth potential.
Recent Initiatives: Recent initiatives include focusing on reducing operating costs and exploring strategic partnerships.
Summary
Puma Biotechnology is a smaller player in the oncology space heavily reliant on the performance of NERLYNX. Competition from established pharmaceutical giants poses a significant challenge. Successful expansion into new markets and strategic partnerships are crucial for its future growth. Cash flows are a concern, and profitability needs to be addressed for the company to succeed long term.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual circumstances and consultation with a qualified financial advisor. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Puma Biotechnology Inc
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2012-04-24 | Founder, Chairman, President, CEO & Secretary Mr. Alan H. Auerbach | ||
Sector Healthcare | Industry Biotechnology | Full time employees 172 | |
Full time employees 172 | |||
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.